anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Breakfast skipping, which is a common, yet unhealthy dietary habit among young women, has been strongly associated with over-eating (especially in the evening), weight gain, and obesity. Breakfast skipping has also been shown to reduce cognitive function in this population. However, it is unclear as to whether the addition of breakfast, with specific emphasis on increased dietary protein, leads to improvements in these outcomes. This study will provide mechanistic evidence supporting the addition of a protein-rich breakfast to improve and/or re-establish appetite control, energy intake regulation, and cognitive function in overweight/obese 'breakfast skipping' young women. 22 overweight and obese 'breakfast skipping' adolescent girls will participate in the following randomized within-subject crossover-design breakfast study. The participants will randomly complete the follow breakfast patterns at home for 6 days: 1) Breakfast Skipping; 2) Consumption of Normal Protein breakfast meals(i.e., 350 kcal; 15% of the meal as protein, 65% CHO, \& 20% fat); and 3) Consumption of Protein-Rich breakfast meals (i.e., 350 kcal; 40% of the meal as protein, 40% CHO, \& 20% fat). On the 7th day of each pattern, the participants will report to the MU-Brain Imaging Center in the morning to complete the respective 10-h testing day. The participants will begin the testing day by either skipping breakfast or consuming their respective breakfast meal. Blood samples and assessments of perceived appetite, pleasure/reward, and cognitive function will be collected/completed at specific times throughout the day. A standardized lunch will also be provided. Prior to dinner, a brain scan will be completed using functional magnetic resonance imaging (fMRI) to identify brain activation patterns in response to food pictures. Following the fMRI, the participants will be provided with an ad libitum dinner buffet to consume of the facility. They will also be given evening snacks to consume ad libitum, at home throughout the remainder of the day. There is a 7-day washout period between each breakfast pattern. Primary outcomes include morning, mid-day, afternoon, and evening appetite, satiety, pleasure/reward, hormonal responses (plasma glucose, insulin, ghrelin, and PYY concentrations), brain activation patterns, evening energy intake, and daily energy intake.
Face-to-Face Individualized Comprehensive Self-Management (CSM-FF) Group. Participants in the individualized CSM-FF group will be scheduled for 9 weekly sessions with the nurse therapist followed by post-intervention follow-up assessment.
PURPOSE:To obtain human T cell hybridoma producing human B cell growth factor or human B cell differentiation factor and capable of being cultured permanently. CONSTITUTION:The hypoxanthine-guanine-phosphoribosyl-transferase-less human leukemia T cell derived from human leukemia T cell is used as a parent cell, and is fused with human T cell separated and purified from various T cells derived from peripheral blood, marrow, lymph node, spleen, etc., in a proper medium in the presence of a fusion accelerating agent (e.g. a polyetylene glycol having an average molecular weight of 1,000-6,000). The fused cells are cultured in a conventional medium for selection of hybrid, e.g. a medium containing hypoxanthine, aminopterin and thymidine to separate the desired fused cell. The obtained human T cell hybridoma strain is proliferated in a conventional medium to cause cloning, and is separated to the separate fused cell strains.
The purpose of this paper is to establish an easy-to-use questionnaire for subjective evaluations of visually induced motion sickness (VIMS) and visual fatigue caused by stereoscopic 3D (s3D) images. We reviewed previously used questionnaires and extracted 51 important subjective evaluation items from them. We then recruited 251 participants to observe 3D images designed to easily induce sickness or visual fatigue, and we asked them to respond to the 51 items. As a result of exploratory factor analysis, four factors were extracted according to their factor loadings, and the number of items was reduced to 21. Further processing by confirmatory factor analysis led to the selection of 15 items. Comparing mean ratings for each factor before and after item reduction indicated that item reduction did not significantly affect the participant responses. Therefore, the 15-item Visually Induced Symptoms Questionnaire (VISQ), can be used to evaluate VIMS and s3D visual fatigue.
Inject 3ml PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm.
In view of dose-dependent adverse reactions and since pregabalin is eliminated primarily by renal excretion, adjust the dose in adult patients with reduced renal function. The use of pregabalin in pediatric patients with compromised renal function has not been studied.

Base the dose adjustment in patients with renal impairment on creatinine clearance (CL cr), as indicated in Table 2. To use this dosing table, an estimate of the patient's CL crin mL/min is needed. CL crin mL/min may be estimated from serum creatinine (mg/dL) determination using the Cockcroft and Gault equation: 

Next, refer to the Dosage and Administration section to determine the recommended total daily dose based on indication, for a patient with normal renal function (CL crgreater than or equal to 60 mL/min). Then refer to Table 2 to determine the corresponding renal adjusted dose. 

(For example: A patient initiating pregabalin therapy for postherpetic neuralgia with normal renal function (CL crgreater than or equal to 60 mL/min), receives a total daily dose of 150 mg/day pregabalin. Therefore, a renal impaired patient with a CL crof 50 mL/min would receive a total daily dose of 75 mg/day pregabalin administered in two or three divided doses.) 

For patients undergoing hemodialysis, adjust the pregabalin daily dose based on renal function. In addition to the daily dose adjustment, administer a supplemental dose immediately following every 4-hour hemodialysis treatment (see Table 2).
PURPOSE:To obtain a bath water cleaning agent, containing a specific hydriodate and capable of preventing offensive smell, etc., emitted in allowing the bath water to stand after bathing. CONSTITUTION:A bath water cleaning agent obtained by adding an extender, e.g. neutral inorganic salt, etc., and a binder, e.g. sodium carboxymethyl cellulose (CMC-Na) or gum arabic, to a compound expressed by the formula InX (n is 1 or 2; X is K, Na, Li, Mg, Ca or NH4) and molding the resultant blend into tablets. The compound expressed by the formula is added in an amount of 1-30ppm, particularly 3-10ppm based on the bath water. Thereby unpleasant sliminess of the bottom part of a bathtub can be prevented without problems of corrosion in metallic parts.
The investigators will carry out a prospective analytical observational clinical study at the Clinical Hospital of the University of Chile. In total 15 patients will be recruited, in who a frontal electroencephalographic signal will be recorded using a SedLine® monitor, and propofol concentration will be estimated using the Marsh model. First, the concentration of propofol at the loss of consciousness (LOS) will be recorded in the presence of remifentanil (7.5 ng/mL). Then, patients will be intubated and remifentanil will be decreased to 4 ng/mL. After that, the concentration of propofol that caused the LOS will be maintained for 20 minutes. Finally, propofol will be increased in steps of 0.3 mcg/mL for 7 min, until an episode of burst suppression will be observed. In the complete protocol, EEG activity will be acquired using a SedLine® monitor.
A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated  Borrelia burgdorferi , an adjuvant in an amount effective to enhance the immunogenicity of the inactivated  Borrelia burgdorferi  isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first  Borrelia burgdorferi  isolate and a second, non-crossprotective  Borrelia burgdorferi  isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third  Borrelia burgdorferi . Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated  Borrelia burgdorferi  and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated  Borrelia burgdorferi  and antigenic subunits and a suitable carrier. Methods of immunizing an animal against  Borrelia burgdorferi  infection which comprise administering to the animal a dose of a bacterin provided herein are also provided.
Castle Creek is developing a two-component therapeutic product for the treatment of moderate to severe localized scleroderma (morphea). The first component is FCX-013, an autologous genetically modified human dermal fibroblast (GM-HDFs) cell product that is genetically modified with a lentiviral vector (LV) to express human matrix metalloproteinase 1 (MMP1). MMP1 is also known as interstitial collagenase or fibroblast collagenase and is an enzyme that under normal physiological conditions breaks down the extracellular matrix. Specifically, MMP1 breaks down interstitial collagens, types I, II and III. In addition, the FCX-013 cells are also transduced with genetic constructs that encode the RheoSwitch Therapeutic System® (RTS®) an inducible promotor system that in the presence of a small molecule activator ligand controls expression of the MMP1 gene. The RTS® is activated to express MMP1 by the oral administration of the small molecule component. The purpose of this open-label single arm Phase 1/2 study is to investigate the safety and effectiveness of FCX-013 plus veledimex.
The aim of this study was to determine the effect of Bubble-PEP device compared to ACBT in asthmatic patients. This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group A will be treated with ACBT and group B will be treated with bubble-PEP device. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25
The traditional Chinese medical theory of 'Oral taking and External using' and 'Supporting healthy energy to eliminate evils' are used, and a novel method of 'Suspension medicine bait oral taking' is created in this invention, so the cure rate of shellfish disease is raised. The technological key is that, 1, The floatable substance is used as carrier, such as soy-bean milk protein etc., which can be floated on water for long time and likely ate by shellfish. 2, Such substance can be taken by shellfish through carrier utilizing property of some drug can combined with protein carrier and added with variety of effective medicinal content. 3, The main content is composed of sulfa drugs, vitamin and Chinese medicinal herb. 4, Efficacy is that it can effectively prevent and cure communicable disease of shellfish, quickly control death rate and promote recovery. 5, Dosage and usage, 1 bottle/2000 shellfish everyday, filtered soy-bean milk made from 1 kg soy-bean and added with one bottle of medicine, then sprayed and fed in 2-3 times
The overall incidence rate of sellar tumors is 10-20% of brain tumors. Most of the initial symptoms of this tumor are visual or visual impairment. One of the primary complications of these operations is visual impairment, which directly relates to the quality of patients' life. Flash visual evoked potentials (FVEPs) is an important means of intraoperative visual function evaluation under general anesthesia. Intraoperative visual function damage can be avoided or reduced by observing the changing of FVEPs waves to guide the choice of surgical path.

However, since the diversity of anesthetic drugs and methods, there is still a great uncertainty impact on FVEPs, which will interfere with the interpretation and judgment of surgeons and neuroelectrophysiological physicians respect to the changes of FVEPs amplitude and latency, and further affect the operation decision-making. Therefore, it is urgent to establish a perfect anesthesia method for intraoperative monitoring of FVEPs. Although total intravenous anesthesia has been widely accepted for FVEPs monitoring, there are still some limitations, such as the possibility of intraoperative body movement and cough due to the restriction of muscle relaxant use under electrophysiological monitoring, as well as the depression on FVEPs of high maintained dosage under total intravenous anesthesia. The purpose of this study was to investigate the feasibility of FVEPs monitoring during endoscopic sellar tumor resection under combined intravenous anesthesia compared with total intravenous anesthesia.
A robotic system that can be used to treat a patient. The robotic system includes a mobile robot that has a camera. The mobile robot is controlled by a remote station that has a monitor. A physician can use the remote station to move the mobile robot into view of a patient. An image of the patient is transmitted from the robot camera to the remote station monitor. A medical personnel at the robot site can enter patient information into the system through a user interface. The patient information can be stored in a server. The physician can access the information from the remote station. The remote station may provide graphical user interfaces that display the patient information and provide both a medical tool and a patient management plan.
There was no evidence of carcinogenicity in a 113-week oral study in mice at doses up to 40 mg/kg/day (10 times the maximum recommended human dose [MRHD] on a mg/m 2 basis). There was also no evidence of carcinogenicity in rats orally dosed at up to 40 mg/kg/day for 71 weeks followed by 20 mg/kg/day (20 and 10 times the MRHD on a mg/m 2 basis, respectively) through 128 weeks. 

Memantine produced no evidence of genotoxic potential when evaluated in the in vitroS. typhimurium or E. coli reverse mutation assay, an in vitro chromosomal aberration test in human lymphocytes, an in vivo cytogenetics assay for chromosome damage in rats, and the in vivo mouse micronucleus assay. The results were equivocal in an in vitro gene mutation assay using Chinese hamster V79 cells. 

No impairment of fertility or reproductive performance was seen in rats administered up to 18 mg/kg/day (9 times the MRHD on a mg/m 2 basis) orally from 14 days prior to mating through gestation and lactation in females, or for 60 days prior to mating in males.
The present invention relates to a gelatine product comprising a core component, wherein the core component is partially or completely encapsulated by a gelatine gel. The gelatin gel is made from a homogeneous casting compound containing the following components dissolved in water: -3 to 20% by weight of gelatin having an average molecular weight of at least 130kDa, preferably at least 145kDa, as determined by gel chromatography, the proportion of molecular weight moieties exceeding 100kDa being at least 35%, preferably at least 45% by weight; -up to 60% by weight, preferably from 15% to 60% by weight, of a glucose syrup having a viscosity of less than 1000 mPa-s, preferably less than 800 mPa-s, measured at 80% by weight dry matter content and at a temperature of 60 ℃; and-up to 60 wt. -%, preferably 15 to 60 wt. -% of sucrose, wherein the dry matter content of the casting compound is at least 70 wt. -%. The invention also relates to a method for manufacturing such a gelatine product.
Corneal neovascularization is a sight threatening condition and is also a well recognized risk factor for corneal graft failure. Current standard of care to prevent graft rejection includes use of topical steroids and immunosuppressants. These do not address corneal neovascularization. The cornea is kept in its avascular state by a complex interaction of signal proteins and host receptors, with a vital role played by the soluble VEGF-receptor 1. In any condition of chronic corneal inflammation or hypoxia, the balance may tip in favour of pro-angiogenic factors, and neovascularization will ensue. Early and limited studies have examined the effect of subconjunctival or intracorneal administration of monoclonal antibodies to VEGF (bevacizumab, ranibizumab) in combating corneal neovascularization. Most report subtotal or temporary regression. The development of aflibercept (also known as VEGF Trap-Eye) offers new hope of more effectively combating the problem. In this study, research will be conducted to investigate and assess safety of subconjunctival aflibercept injection in patients with corneal neovascularization undergoing corneal transplantation.

This is a phase 1, prospective, randomized, open label clinical trial that will enroll 10 corneal transplant patients with corneal neovascularization in one or more quadrants crossing more than 0.5 mm over the limbus at the time of corneal transplantation.
After a 1 week baseline, volunteers will consume two packets of placebo powder stirred into water for three weeks. Following a two week washout period, volunteers will cross-over to grape powder for three weeks.
Group 2: (n=190) Following their initial screen, these participants will be offered community based hepatitis C care and treatment. Hepatitis C care, transient elastography and DAA treatment will be delivered at the primary healthcare centre only.
PURPOSE OF REVIEW: This review provides an overview of the history, mechanism of action, and expected treatment effects of the anti-obesity medication (AOM), phentermine. It also includes a summary of recent research and practical guidance for prescribing clinicians.
RECENT FINDINGS: Recent research on phentermine is sparse and consists primarily of observational studies with methodologic limitations. These studies suggest that phentermine use is associated with clinically significant weight loss in adults and that the medication is generally well tolerated. Large-scale observational studies evaluating phentermine's safety have not identified an increased risk of cardiovascular events or elevations in blood pressure. There is no data to support the notion that phentermine is addictive. Although it remains the most commonly prescribed AOM in the USA, phentermine has little rigorous research to support its efficacy and safety in long-term treatment, which creates a dilemma with guideline-recommended chronic use of AOMs. While we await forthcoming conclusive data on this front, clinicians may consider using phentermine long-term in selected patients, if such prescribing is consistent with local regulatory statutes.
The incidence of thyroid cancer has increased rapidly in recent years, especially in women. Differentiated thyroid cancer takes the largest proportion in thyroid cancer, but it has a good prognosis. For early differentiated thyroid cancer, surgery is the main treatment. Traditional open surgery would leave a scar on the neck, which is especially troublesome for female patients. However, emerging minimally invasive procedures, such as endoscopy-assisted subclavian approach, robot-assisted transaxillary or transoral approach, etc., can avoid the scar on the neck, resulting in better aesthetic effect, which would have an impact on the quality of life of patients to a certain degree.

This study intend to follow up patients regularly with early differentiated thyroid cancer undergoing surgery according to a prospective cohort design. The evaluation questionnaires including quality of life, voice and scar would be completed to demonstrate that minimally invasive surgery is better than traditional open surgery not only in the way of effectiveness, but also in the quality of life. We hope to provide reliable evidence for clinical practice by this study.
OBJECTIVES: I. Determine the toxic effects of interferon alfa, interleukin-2, gemcitabine, and fluorouracil in patients with metastatic or unresectable renal cell cancer. II. Evaluate the feasibility and possible therapeutic anticancer efficacy of this therapy in these patients. III. Determine the duration of response, survival, and improvement of quality of life in these patients.

OUTLINE: Patients receive fluorouracil IV on days 1, 8, 15, and 22, followed by gemcitabine IV over 30 minutes on days 29, 36, 43, and 50. Interferon alfa is administered subcutaneously 3 times weekly beginning on day 1. Beginning on day 2, interleukin-2 is administered subcutaneously 3 times weekly for the first 4 weeks of the treatment course. Treatment is repeated every 8 weeks for up to 4 courses in the absence of unacceptable toxic effects and disease progression. Following chemobiotherapy, maintenance therapy is administered to patients with stable or responding disease. Patients receive subcutaneous interferon alfa 3 times weekly at the maximum tolerated dose until disease progression or for a maximum of 1 year. A quality of life assessment is completed weekly. Patients are followed until death.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 18-24 months.
S-Ketamine (0.125 mg / kg body weight). (0.625mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).
For these cases, the regular protocol of the study site is observed. The operator has the plan at their disposal projected on a screen in the operating theater. The preparation of the bony bed and the insertion of the implant are performed freehand, without any guidance. The positions and directions are determined with the naked eye, observing the plan projected on the screen. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.